Eris Lifesciences Limited Q2FY22 Revenues at INR 3,597 mn, up 9.0% YoY

Eris Lifesciences Limited Q2FY22 Revenues at INR 3,597 mn, up 9.0% YoY

Consolidated Financial Highlights:


(INR million)

Q2FY22 Q2FY21 YoY (%) H1FY22 H1FY21 YoY (%)
Revenue 3,597 3,300 9.0% 7,089 6,232 13.8%
Gross Profit 2,933 2,662 10.2% 5,737 5,018 14.3%
EBITDA 1,398 1,248 12.1% 2,663 2,288 16.4%
EBITDA Margin 38.9% 37.8% 107bps 37.6% 36.7% 85bps
PAT 1,184 1,077 9.9% 2,251 1,967 14.4%
PAT Margin 32.9% 32.6% 27bps 31.7% 31.6% 18bps

Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd., said, “Our branded formulations business has outperformed the market growth by nearly 50% since pre-pandemic times, driven by strong growths in our cardio-metabolic, VMN and CNS therapies. Our focus on building strong brands in fast growing therapies coupled with several patent expiration opportunities will enable us to sustain this growth trajectory.”

Mr. Krishnakumar V, Executive Director & Chief Operating Officer of Eris Lifesciences Ltd., added, “Our consolidated revenue has grown by ~ 14% and Net Profit by 14.4% in the first half of this financial year. Our portfolio of power brands in cardio-metabolic and VMN continues to drive our growth. Nine out of our Top-15 mother brands are ranked among the Top-5 within their respective segments. Our latest-generation Diabetes products Zomelis and Gluxit continue to enjoy #1 market ranks and robust growth. Of the 10 new product launches planned for FY22, we have launched 4 products in the first half of the year; we have more launches planned in H2 in the areas of Cardio-Metabolic, Wellness and Women’s Health. We have an exciting period of organic growth coming in the next 4 – 5 years, driven by multiple factors like consolidation of power brands franchise, new launch pipeline, expansion of physician coverage and therapeutic diversification. We continue to look for high-return in-licensing and acquisition opportunities, in order to supplement our organic growth initiatives.”

News Links

Copyright © 2022 Eris Lifesciences Limited. All Rights Reserved.